Drug profile · INN
pexidartinib
TURALIO
pexidartinib (TURALIO) is a tyrosine-protein kinase receptor flt3 inhibitor.
EMA: refused Antineoplastic and immunomodulating agents (L01) L01XE
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — pexidartinib
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
pexidartinib (TURALIO) is a tyrosine-protein kinase receptor flt3 inhibitor.
Key facts
INN pexidartinib
Brand TURALIO
Mechanism Tyrosine-protein kinase receptor FLT3 inhibitor
Target Macrophage colony-stimulating factor 1 receptor
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01XE
Mechanism of action
Tyrosine-protein kinase receptor FLT3 inhibitor
Primary target: Macrophage colony-stimulating factor 1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | refused | — |
Related & competitor drugs
Frequently asked questions
What is pexidartinib?
pexidartinib (TURALIO) is a tyrosine-protein kinase receptor flt3 inhibitor.
What is the brand name for pexidartinib?
TURALIO is a marketed brand name for pexidartinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.